(CercleFinance.com) – Novartis announced on Monday that it has entered into a licensing agreement with Chinese biotech BeiGene for an immunotherapy under development in the treatment of lung cancer.
The Swiss biopharmaceutical group specifies that the collaboration concerns ociperlimab (BGB-A1217), an inhibitor of the T lymphocyte immunoreceptor with immunoglobulin and ITIM domain (TIGIT) which could constitute a promising avenue in the treatment of cancer.
Ociperlimab is currently in two Phase III clinical studies in the treatment of non-small cell lung cancer, as well as in other tests for the treatment of solid tumors.
The conclusion of this license will result in the payment of an upfront payment of $ 300 million to BeiGene, which could collect $ 700 million from Novartis if the option on the molecule is exercised.
Copyright © 2021 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
